Mean annualized relapse rate not different before vs after controlled ovarian stimulation.
News and Features
On appeal, the court looked at a variety of cases to determine whether Dr K had a physician-patient relationship with Mr B based on the phone call between him and Dr M.
The approval was supported by data from the randomized, double-blind, placebo-controlled phase 3 LAVENDER study.
Global Alzheimer disease pathology lower in patients following these dietary patterns, specifically less beta-amyloid load
Limits on acetaminophen levels in combination opioid products linked to declines in liver injuries; Investigational Alzheimer disease drug fails to show efficacy; Bempedoic acid assessed for reducing major adverse cardiovascular events; Commercial blood test for suspected TBIs; Mammography regulations updated.
Solanezumab is a humanized monoclonal antibody designed to increase clearance of soluble amyloid beta (Aβ) from the brain by binding to aggregated forms of Aβ.
The table provided is a review of notable updates that occurred in February 2023 for investigational products in development.
Any vitamin D supplement exposure was associated with 40 percent lower dementia incidence
Eplontersen is an investigational ligand-conjugated antisense medicine.
Alinity i TBI lab test measures complementary biomarkers in blood plasma and serum that are tightly correlated to brain injury when elevated.
The sBLA is supported by data from the confirmatory phase 3 Clarity AD trial, which included patients with early Alzheimer disease.
Authors note a significantly reduced levodopa-induced dyskinesia and motor severity score opposite to the treated side
Skyclarys activates the Nrf2 pathway which is involved in the cellular response to oxidative stress.
To assess the potential risk, the FDA is working with manufacturers of neonatal incubators and evaluating data from their products.
No signs of higher risk seen for developmental disorders
Risk for all-cause, vascular dementia was increased with number of regularly used laxative types
Findings seen for both chronic migraine and high-frequency episodic migraine patients based on pain-free state
Austedo XR is a vesicular monoamine transporter 2 inhibitor.
No such association seen for Black older adults followed for 15 years, regardless of sleep duration
Reduction in risk was greatest for those with history of ischemic heart disease or stroke